- Home
- MBOT vs MGNX Comparison
MBOT vs MGNX Comparison
Compare MBOT & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBOT
- MGNX
- Stock Information
- Founded
- MBOT 2010
- MGNX 2000
- Country
- MBOT United States
- MGNX United States
- Employees
- MBOT N/A
- MGNX N/A
- Industry
- MBOT Medical/Dental Instruments
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- MBOT Health Care
- MGNX Health Care
- Exchange
- MBOT Nasdaq
- MGNX Nasdaq
- Market Cap
- MBOT 94.6M
- MGNX 87.7M
- IPO Year
- MBOT N/A
- MGNX 2013
- Fundamental
- Price
- MBOT $2.60
- MGNX $1.61
- Analyst Decision
- MBOT Strong Buy
- MGNX Hold
- Analyst Count
- MBOT 1
- MGNX 9
- Target Price
- MBOT $9.00
- MGNX $5.33
- AVG Volume (30 Days)
- MBOT 998.8K
- MGNX 1.3M
- Earning Date
- MBOT 08-13-2025
- MGNX 08-05-2025
- Dividend Yield
- MBOT N/A
- MGNX N/A
- EPS Growth
- MBOT N/A
- MGNX N/A
- EPS
- MBOT N/A
- MGNX N/A
- Revenue
- MBOT N/A
- MGNX $154,050,000.00
- Revenue This Year
- MBOT N/A
- MGNX N/A
- Revenue Next Year
- MBOT N/A
- MGNX N/A
- P/E Ratio
- MBOT N/A
- MGNX N/A
- Revenue Growth
- MBOT N/A
- MGNX 255.31
- 52 Week Low
- MBOT $0.82
- MGNX $0.99
- 52 Week High
- MBOT $3.38
- MGNX $5.77
- Technical
- Relative Strength Index (RSI)
- MBOT 54.60
- MGNX 59.02
- Support Level
- MBOT $2.44
- MGNX $1.34
- Resistance Level
- MBOT $2.77
- MGNX $1.65
- Average True Range (ATR)
- MBOT 0.13
- MGNX 0.11
- MACD
- MBOT 0.01
- MGNX 0.04
- Stochastic Oscillator
- MBOT 63.83
- MGNX 91.40
About MBOT Microbot Medical Inc.
Microbot Medical Inc is a clinical-stage medical device company specializing in the research, design and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. It is focused on leveraging its robotic technologies to redefine surgical robotics while improving surgical outcomes for patients. Using its LIBERTY technological platform, the company is developing the first-ever fully disposable robot for various endovascular interventional procedures.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.